AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03805854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation of the prefrontal cortex
Description: 10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5\*5 cm rubber placed at electrode positions F3 and F4 according to the international 10-20 system.
Study NCT03058198 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 89Zr-ABT806 PET
Description: Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
Study NCT02994485 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
Study NCT06374680 — intervention group
Intervention type: PROCEDURE
Intervention: laminectomy at C3 level
Description: laminectomy at C3 level
Study NCT02941770 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity behavior change
Description: Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
Study NCT02941770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
Study NCT03037307 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Contol
Description: Three dabs of positive control adhesive cream for upper denture, as per application instructions.
Study NCT03037307 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Negative Control
Description: No adhesive
Study NCT03118453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active implementation clinics
Description: Physical therapy treatment as the physical therapist chooses
Study NCT03118453 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive implementation clinics
Description: Physical therapy treatment as the physical therapist chooses
Study NCT02979366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S64315 once a week
Description: S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
Study NCT02979366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S64315 twice a week
Description: S64315 will be administered via i.v. infusion from 30 minutes and up to 3 hours twice every week (28- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
Study NCT00211172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beta-blocker adherence after an AMI
Description: The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.
Study NCT01816776 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment Group (transvenous stimulation of the phrenic nerve)
Description: device implant, optimal medical therapy and device initiation 1 month post implant.
Study NCT01816776 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Control Group (Optimal Medical Therapy)
Description: device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
Study NCT03915444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel + Cisplatin + Gemcitabine
Description: Cisplatin 25mg/m2 in 500 mL of NS over 60 minute IV infusion on days 1 and 8 repeated every 21 days.~Gemcitabine 1000mg/m2 in 500 mL\* over 30 minute IV infusion on days 1 and 8 repeated every 21 days.~Post cisplatin hydration: IV fluids up to 1000 mL (with additives as clinically indicated) IV given as infusion on days cisplatin is administered on days 1 and 8 repeated every 21 days.
Study NCT03190499 — intervention group
Intervention type: OTHER
Intervention: Family based assessment
Description: Family of the children will be assessed with questionnaires about their child health condition.
Study NCT02439307 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: 1200 mg of rifaximin for 2 weeks.
Study NCT02439307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 2 weeks
Study NCT03576014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BD03
Description: BD03 is to be administered intramuscularly 6 weeks and 2 weeks prior to kidney transplant and 2\~4 weeks after the transplant.
Study NCT02413944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACTH stimulation test
Description: ACTH stimulation test
Study NCT03715725 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Administration according to clinical practice
Study NCT03715725 — intervention group
Intervention type: DRUG
Intervention: Apixaban (Eliquis)
Description: Administration according to clinical practice
Study NCT03715725 — intervention group
Intervention type: DRUG
Intervention: Dabigatran etexilate (Pradaxa)
Description: Administration according to clinical practice
Study NCT03715725 — intervention group
Intervention type: DRUG
Intervention: Warfarin (Marevan)
Description: Administration according to clinical practice
Study NCT01804049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
Study NCT01804049 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
Study NCT03443089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test formulation
Description: Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.
Study NCT03443089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference formulation
Description: Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.
Study NCT01484652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COV795
Description: 2 tablets taken every 12 hours
Study NCT01484652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets taken every 12 hours
Study NCT03096639 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diaphragmatic Pacing Therapy DPTS
Description: Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.
Study NCT01886235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Microscopy
Description: Undergo intravital microscopy
Study NCT01886235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium Injection
Description: Given IV
Study NCT01886235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01886235 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT02378285 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ACP
Description: ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
Study NCT02378285 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
Study NCT04349358 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FDG and FCH PET/CT
Description: * during the initial myeloma check-up : FDG and FCH PET/CT exams (maximum 21 days after inclusion)~* just before maintenance treatment, respecting a minimum interval of 2 weeks after the last course of chemotherapy : FDG and FCH PET/CT exams
Study NCT04541485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWRX2003
Description: Intramuscularly injection at pre-defined injection sites
Study NCT04541485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscularly injection at pre-defined injection sites
Study NCT01118715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression glove
Description: A compression glove worn during recovery from distal radius fracture
Study NCT01804114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pain management following hernia repair
Description: Continuous infusion of local anesthetic via pain pump following hernia repair
Study NCT01804114 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for pain management following hernia repair
Description: Continuous infusion of placebo via pain pump following hernia repair
Study NCT05185648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard trauma care taining
Description: trauma care training
Study NCT01009021 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: potassium diclofenac
Description: potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment
Study NCT02118948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abuse-focused intervention
Study NCT02118948 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sexual behavior-focused intervention
Study NCT02613520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine
Description: Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
Study NCT02613520 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Sodium chloride
Study NCT03444571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: revision surgery
Description: If DNA based diagnosis detects infection, standard revision surgery will be conducted
Study NCT03081598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PBI-4050
Description: Soft gelatine capsule containing 200 mg of the active ingredient per capsule
Study NCT03452085 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: artificial saliva spray (AS)
Description: cross over design
Study NCT03081598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo soft gelatine capsule
Study NCT03081598 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo soft gelatine capsule
Study NCT04104295 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound following X-ray
Description: A short (less than 10 minutes) ultrasound (US) scan of the abdomen within 2 hours of the routine X-ray (XR). The performer will be a physician who received a focused training on relevant US views, blinded to the XR image and report.
Study NCT02563925 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain radiotherapy or Stereotactic Radiosurgery
Study NCT02563925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study NCT02563925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HER2 directed therapy
Study NCT02563925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Study NCT02617017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
Study NCT02617017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
Study NCT04869176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electrocardiogram
Description: Recording of the electrical activity of the heart during sleep; sleep phases were evaluated. The bed was initially in horizontal position and tilted for 30° head-up after 20 minutes of continuous tracing.
Study NCT04869176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monitoring of vital functions
Description: Measuring of heart rate, breathing frequency, arterial oxygen saturation and body temperature while recording ECG.
Study NCT04869176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate 5 mg/kg
Description: Caffeine in the form of suspension was given to the newborns.
Study NCT01913197 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An MRI-based technique to identify prostate cancer
Study NCT02613520 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PfSPZ Challenge (for CHMI)
Description: live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Study NCT00879437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic acid
Description: Daily (pre-XRT, During XRT, Post-XRT and Maintenance Therapy) Started at 15 mg/kg/day divided into three doses a day as soon as patients have recovered from surgery but no later than the first day of XRT.~Dosage will be adjusted in increments of 5 mg/kg/day every 3-5 days to achieve and maintain trough concentrations between 85 and 115 mcg/ml
Study NCT00879437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: All patients will receive bevacizumab (10 mg/kg iv) during the maintenance phase every two weeks for a maximum duration of therapy of 24 months.
Study NCT00879437 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will start within 30 days of the definitive surgical procedure. Primary brain malignant gliomas will receive a total dose of between 54.0 and 59.4 Gy in 30-33 fractions over 6-7 weeks. Total dose will be 54.0 Gy for completely resected tumors and brainstem gliomas. The total dose will be 59.4 if the tumor is located in the brain but not the brainstem, and the tumor was incompletely resected. Primary spinal cord malignant gliomas will receive a total dose of between 50.4-54 Gy in 28-30 fractions over 5-6 weeks.
Study NCT02613520 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ Challenge (for CHMI)
Description: live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
Study NCT03452085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: maritime throat spray (TT)
Description: cross over design
Study NCT03452085 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: maritime throat spray (TT)
Description: cross over design
Study NCT04335526 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cholestyramine Resin
Description: Change bile acid pool by cholestyramine treatment
Study NCT04022928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP
Description: , For PRP preparation, specialized platelet concentrate separator containing acid citrate dextrose as anticoagulant and a specific separator gel that harvest PR, preventing contamination of red blood cells and leukocytes were used.
Study NCT00630019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% levofloxacin ophthalmic solution
Description: Topical application
Study NCT00630019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% moxifloxacin hydrochloride ophthalmic solution
Description: Topical application
Study NCT00595686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNX-5422
Description: dose escalated; tablets every other day; undetermined duration until disease progression
Study NCT01736241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3053102
Study NCT01736241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03481218 — intervention group
Intervention type: OTHER
Intervention: The World Health Organization Quality of Life (WHOQOL) -BREF
Description: The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.
Study NCT03481218 — intervention group
Intervention type: OTHER
Intervention: The Satisfaction With Life Scale - SWLS
Description: The SWLS is a short 5-item instrument designed to measure global cognitive judgments of satisfaction with one's life.
Study NCT03481218 — intervention group
Intervention type: OTHER
Intervention: Big Five Inventory - BFI; John in Srivastava, 1999
Description: The Big Five Inventory (BFI) is a self-report inventory designed to measure the Big Five dimensions.
Study NCT02358343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Engagement Interview
Description: An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
Study NCT02358343 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
Study NCT02358343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressant Drug Therapy
Description: The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
Study NCT01249365 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK580299 (Cervarix)
Description: 3-dose schedule intramuscularly vaccination
Study NCT01439230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 10 mg Tablet